



NEWS RELEASE

Teijin Signs Technical Advisory Agreement with Professor Dario Campana, a World-renowned Authority in CAR-T Cell Therapy Research

Tokyo, August 19, 2026: [Teijin Limited](#) today announced the signing of a technical advisory agreement with Professor Dario Campana, M.D., Ph.D., a noted authority on cell therapies including chimeric antigen receptor (CAR)-T cells, one of the most promising cell and gene therapies for leukemia and cancer. He is a professor in the Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore. Professor Campana who is involved in the technology development of CAR-T cell therapy, will help Teijin Regenet advance manufacturing technologies and quality control systems for cell therapy products. The goal is to support pharmaceutical and biotechnology companies and benefit the patients that receive their therapies.

Through this agreement, [Teijin Regenet Co., Ltd.](#), which operates regenerative medicine contract development and manufacturing organization (CDMO) businesses within Teijin group, will strengthen its global expertise, optimize its manufacturing processes and improve quality for cell and gene therapies, including CAR-T cells.

“CAR-T cell therapy has become an important tool in the treatment of cancer,” said Professor Campana. “It is a privilege to work with Teijin Regenet Co., Ltd., as it seeks to expand access to CAR-T and other cell therapies for patients in Japan and around the world.”

“While CAR-T cell therapy is expected to yield high therapeutic efficacy, it is an area that requires advanced expertise in manufacturing technology and quality control,” said Takeshi Hosoyama, president, Teijin Regenet Co., Ltd. “Through this partnership with Professor Dario Campana, who has been a leader in the CAR-T cell therapy field, we will further strengthen our technological foundation and contribute to the smooth transfer of manufacturing and high-quality products for our customers' developed products.”

Partnership Details

Under this agreement, Professor Campana will share his expertise in cell therapy products by providing:

- (1) Advice on designing manufacturing processes and optimizing manufacturing conditions for CAR-T cells transferred from development to manufacturing.
- (2) Provision of cutting-edge knowledge on cell therapy technologies, including next-generation CAR-T cell therapy
- (3) Strategic advice to enhance technological capabilities and competitiveness in Teijin and Teijin Regenet's regenerative medicine CDMO business

CAR-T cell therapy is a highly personalized cancer treatment that is manufactured individually for each patient. During the process of transitioning manufacturing methods established during the research and development stage to commercial production, challenges such as cell proliferation and quality reproducibility may arise. Therefore, advanced expertise in designing and optimizing manufacturing processes and quality control is required.

As a regenerative medicine CDMO, Teijin Regenet provides comprehensive services from process development for cell therapy products to manufacturing investigational drugs and building manufacturing systems for commercial production. In recent years, the company has been working to optimize manufacturing processes for cell therapies and further strengthen its quality control systems.

Future Outlook

Going forward, the Teijin Group will continue to contribute to the practical application of innovative treatments and the improvement of patients' quality of life by strengthening its technological capabilities in the field of regenerative medicine.

About Professor Dario Campana

Professor Dario Campana previously served as Full Member and Vice-Chair for Laboratory Research in the Oncology Department at St. Jude Children's Research Hospital in Memphis, Tennessee, in the United States, and as a professor of pediatrics at the University of Tennessee. He is currently engaged in research at the National University of Singapore.

He has contributed to the diagnosis of hematologic malignancies and to technologies that advance prediction of leukemia recurrence risk. Additionally, his laboratory, at St. Jude Children's Research Hospital, contributed to the development of many forms of cell therapy, including anti-CD19 chimeric antigen receptors, a foundational technology for CAR-T cell therapy.

About the Teijin Group

Teijin (TSE: 3401) is a global group that co-creates value with Customer-Driven businesses across the Apparel & Industries, Healthcare & Life Solutions, Electronics & Energy, and Specialty Materials domains. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 125 companies employing approximately 15,700 people. Teijin is committed to its Purpose: Pioneering solutions together for a healthy planet. Teijin works together with employees and external partners to achieve its Long-Term Vision: To be a company that supports the society of the future. Teijin posted consolidated revenue of JPY 873.2 billion and total assets of JPY 920.1 billion in the fiscal year ending March 31, 2026.

Visit www.teijin.com

About the Teijin Regenet

Teijin Regenet is a Teijin Group company, established in 2023 and dedicated exclusively to providing contract development and manufacturing services for Cell & Gene Therapy and Regenerative Medicines (CGT&RM). By leveraging the industrialization platform for CGT&RM products the company is building together with academia and companies in Japan and overseas, as well as both “Kashiwa-no-ha Facility” (Kashiwa City, Chiba Prefecture) and “Iwakuni Factory” (Iwakuni City, Yamaguchi Prefecture), the company provides CDMO services that offer one-stop support from manufacturing process development to product manufacturing for startup companies and pharmaceutical companies.

Press Contact

Corporate Communication Department

Teijin Limited

pr@teijin.co.jp